Reuters logo
Celgene raises 2017 revenue, profit forecasts
January 9, 2017 / 5:21 PM / a year ago

Celgene raises 2017 revenue, profit forecasts

Jan 9 (Reuters) - Celgene Corp raised its 2017 revenue and profit forecasts, as the company benefits from new patient market share gains for its flagship multiple myeloma drug, Revlimid.

The Summit, New Jersey-based company said on Monday it expected earnings per share of $7.10-$7.25 and revenue of $13.0 billion-$13.4 billion for 2017.

Celgene had previously forecast full-year earnings of $6.75-$7.00 per share and net product sales of $12.7 billion-$13.0 billion.

Revlimid’s net sales are expected in the range of $8.0 billion to $8.3 billion for 2017. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Sriraj Kalluvila)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below